Skip to main content
SpringerLink
Log in

Cognitive Dysfunction

  • Chapter
  • First Online:
Handbook of Cancer Survivorship

Abstract

Cancer-related cognitive dysfunction (CRCD) is a prevalent problem among cancer survivors and can have a significant negative influence on survivor quality of life and function. In this chapter, we review and summarize the scientific CRCD literature as it pertains to both non-central nervous system and central nervous system cancers. Within each category, we evaluate research on the mechanisms that produce CRCD, such as direct influences of disease, treatment-related influences such as neurotoxic effects or surgery, genetic vulnerabilities, and indirect mechanisms such as inflammation. In addition, we present brief summaries of the emerging scientific and clinical literature on treatments of CRCD. We conclude with a summary and recommendations for future research on both mechanisms and clinical management, with special consideration of newly developed cancer therapies such as immunotherapies that could have a possible influence on survivor cognitive function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001;19(8):812–20.

    Article  CAS  PubMed  Google Scholar 

  2. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123–38.

    Article  PubMed  Google Scholar 

  3. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12(6):612–9.

    Article  PubMed  Google Scholar 

  4. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.

    Article  CAS  PubMed  Google Scholar 

  5. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21(5):407–24.

    Article  CAS  PubMed  Google Scholar 

  6. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12(3):267–75.

    Article  CAS  PubMed  Google Scholar 

  7. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.

    Article  PubMed  Google Scholar 

  8. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.

    Article  PubMed  Google Scholar 

  9. Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med. 1983;34:35–46.

    Article  CAS  PubMed  Google Scholar 

  10. Wieneke M, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4(1):61–6.

    Article  Google Scholar 

  11. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3(3):215–22.

    Article  PubMed  Google Scholar 

  12. Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22(11):2233–9.

    Article  PubMed  Google Scholar 

  14. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143–52.

    Article  CAS  PubMed  Google Scholar 

  15. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115(8):1776–83.

    Article  PubMed  Google Scholar 

  16. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788–93.

    Article  CAS  PubMed  Google Scholar 

  17. Patel SK, Wong AL, Wong FL, Breen EC, Hurria A, Smith M, et al. Inflammatory biomarkers, comorbidity, and neurocognition in women with newly diagnosed breast cancer. J Natl Cancer Inst. 2015 Jun 22;107(8): djv131.

    Google Scholar 

  18. Vardy J, Dhillon HM, Pond GR, Rourke SB, Xu W, Dodd A, et al. Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol. 2014;25(12):2404–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004;101(3):466–75.

    Article  PubMed  Google Scholar 

  21. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–40.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, et al. Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue. Neuroimage Clin. 2015;7:547–54.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Agrawal K, Onami S, Mortimer JE, Pal SK. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas. 2010;67(3):209–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18(2):134–43.

    Article  PubMed  Google Scholar 

  25. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116(1):113–23.

    Article  PubMed  Google Scholar 

  26. Amidi A, Wu LM, Agerbaek M, Larsen PL, Pedersen AD, Mehlsen M, et al. Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. Psychooncology. 2015;24(9):1174–80.

    Article  PubMed  Google Scholar 

  27. Amidi A, Wu LM, Pedersen AD, Mehlsen M, Pedersen CG, Rossen P, et al. Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment. Support Care Cancer. 2015;23(10):2973–9.

    Article  PubMed  Google Scholar 

  28. Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–9.

    Article  PubMed  Google Scholar 

  29. Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML. Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol. 2010;119(2):366–9.

    Article  PubMed  Google Scholar 

  30. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ. Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav. 2013;7(4):491–500.

    Article  PubMed  Google Scholar 

  32. Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat. 2013;137(2):493–502.

    Article  CAS  PubMed  Google Scholar 

  33. Butterfield DA. The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med. 2014;74:157–74.

    Article  CAS  PubMed  Google Scholar 

  34. Castel H, Denouel A, Lange M, Tonon MC, Dubois M, Joly F. Biomarkers associated with cognitive impairment in treated cancer patients: potential predisposition and risk factors. Front Pharmacol. 2017;8:138.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Cheung YT, Lim SR, Ho HK, Chan A. Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. PLoS One. 2013;8(12):e81234.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Kim HJ, Barsevick AM, Fang CY, Miaskowski C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 2012;35(6):E1–e20.

    Article  PubMed  Google Scholar 

  37. Lyon D, Elmore L, Aboalela N, Merrill-Schools J, McCain N, Starkweather A, et al. Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis. Biol Res Nurs. 2014;16(2):160–74.

    Article  PubMed  Google Scholar 

  38. Merriman JD, Von AD, Miaskowski C, Aouizerat BE. Proposed mechanisms for cancer- and treatment-related cognitive changes. Semin Oncol Nurs. 2013;29(4):260–9.

    Article  PubMed  Google Scholar 

  39. Ren X, St Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73.

    Article  CAS  PubMed  Google Scholar 

  40. Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS. Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest. 2012;30(2):135–48.

    Article  CAS  PubMed  Google Scholar 

  41. Wang XM, Walitt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015;72(1):86–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wardill HR, Mander KA, Van Sebille YZ, Gibson RJ, Logan RM, Bowen JM, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int J Cancer. 2016;139(12):2635–45.

    Article  CAS  PubMed  Google Scholar 

  43. Amidi A, Agerbaek M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–83.

    Article  PubMed  Google Scholar 

  44. Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117(7):1369–76.

    Article  CAS  PubMed  Google Scholar 

  45. Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, et al. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014;65(2):192–201.

    Article  CAS  PubMed  Google Scholar 

  46. Aboalela N, Lyon D, Elswick RK Jr, Kelly DL, Brumelle J, Bear HD, et al. Perceived stress levels, chemotherapy, radiation treatment and tumor characteristics are associated with a persistent increased frequency of somatic chromosomal instability in women diagnosed with breast cancer: a one year longitudinal study. PLoS One. 2015;10(7):e0133380.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35(3):729–41.

    Article  PubMed  Google Scholar 

  48. Seigers R, Schagen SB, Van Tellingen O, Dietrich J. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav. 2013;7(4):453–9.

    Article  CAS  PubMed  Google Scholar 

  49. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun. 2007;21(3):251–8.

    Article  CAS  PubMed  Google Scholar 

  50. Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657–64.

    Article  CAS  PubMed  Google Scholar 

  51. Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer. 2012;20(4):831–9.

    Article  PubMed  Google Scholar 

  52. Chae JW, Ng T, Yeo HL, Shwe M, Gan YX, Ho HK, et al. Impact of TNF-alpha (rs1800629) and IL-6 (rs1800795) polymorphisms on cognitive impairment in Asian breast cancer patients. PLoS One. 2016;11(10):e0164204.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26(7):1446–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, et al. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30(Suppl):S99–108.

    Article  CAS  PubMed  Google Scholar 

  55. Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.

    Article  CAS  PubMed  Google Scholar 

  56. Lyon DE, Cohen R, Chen H, Kelly DL, McCain NL, Starkweather A, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, et al. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013;7(4):501–10.

    Article  PubMed  Google Scholar 

  58. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21(2):153–60.

    Article  CAS  PubMed  Google Scholar 

  59. Gilbertson-White S, Aouizerat BE, Miaskowski C. Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms. Biol Res Nurs. 2011;13(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  60. Smith LB, Leo MC, Anderson C, Wright TJ, Weymann KB, Wood LJ. The role of IL-1beta and TNF-alpha signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. Brain Behav Immun. 2014;38:66–76.

    Article  CAS  PubMed  Google Scholar 

  61. Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong JC, Houts AC. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med: JCSM : official publication of the American Academy of Sleep Medicine. 2009;5(2):132–6.

    Google Scholar 

  62. Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, Inouye SK, et al. Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol. 2016;7(4):270–80.

    Article  PubMed  PubMed Central  Google Scholar 

  63. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res. 2002;57:357–84.

    Article  CAS  PubMed  Google Scholar 

  64. Sherwin BB. Estrogen and cognitive aging in women. Neuroscience. 2006;138(3):1021–6.

    Article  CAS  PubMed  Google Scholar 

  65. Sherwin BB. Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev Endocrinol. 2009;5(11):620–7.

    Article  CAS  PubMed  Google Scholar 

  66. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11(7):614–21.

    CAS  Google Scholar 

  67. Zhou L, Fester L, von Blittersdorff B, Hassu B, Nogens H, Prange-Kiel J, et al. Aromatase inhibitors induce spine synapse loss in the hippocampus of ovariectomized mice. Endocrinology. 2010;151(3):1153–60.

    Article  CAS  PubMed  Google Scholar 

  68. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015;121(15):2627–36.

    Article  CAS  PubMed  Google Scholar 

  69. Andreotti C, Root JC, Ahles TA, McEwen BS, Compas BE. Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline. Psychooncology. 2015;24(6):617–23.

    Article  PubMed  Google Scholar 

  70. Feuerstein M. Handbook of cancer survivorship. New York: Springer; 2007. www.pinestreetfoundation.org.

    Google Scholar 

  71. de Ruiter MB, Schagen SB. Functional MRI studies in non-CNS cancers. Brain Imaging Behav. 2013;7(4):388–408.

    Article  PubMed  Google Scholar 

  72. Deprez S, Billiet T, Sunaert S, Leemans A. Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain Imaging Behav. 2013;7(4):409–35.

    Article  PubMed  Google Scholar 

  73. Holohan KN, Von Ah D, McDonald BC, Saykin AJ. Neuroimaging, cancer, and cognition: state of the knowledge. Semin Oncol Nurs. 2013;29(4):280–7.

    Article  PubMed  Google Scholar 

  74. McDonald BC, Saykin AJ. Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations. Brain Imaging Behav. 2013;7(4):374–87.

    Article  PubMed  Google Scholar 

  75. Pomykala KL, de Ruiter MB, Deprez S, McDonald BC, Silverman DH. Integrating imaging findings in evaluating the post-chemotherapy brain. Brain Imaging Behav. 2013;7(4):436–52.

    Article  CAS  PubMed  Google Scholar 

  76. Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH. Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav. 2013;7(4):363–73.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Simó M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.

    Article  PubMed  Google Scholar 

  78. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.

    Article  PubMed  Google Scholar 

  79. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–70.

    Article  PubMed  Google Scholar 

  80. Kam JW, Boyd LA, Hsu CL, Liu-Ambrose T, Handy TC, Lim HJ, et al. Altered neural activation during prepotent response inhibition in breast cancer survivors treated with chemotherapy: an fMRI study. Brain Imaging Behav. 2016;10(3):840–8.

    Article  PubMed  Google Scholar 

  81. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res. 2009;15(21):6665–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):303–11.

    Article  CAS  PubMed  Google Scholar 

  84. Stouten-Kemperman MM, de Ruiter MB, Boogerd W, Veltman DJ, Reneman L, Schagen SB. Very late treatment-related alterations in brain function of breast cancer survivors. J Int Neuropsychol Soc. 2015;21(1):50–61.

    Article  PubMed  Google Scholar 

  85. Wang L, Apple AC, Schroeder MP, Ryals AJ, Voss JL, Gitelman D, et al. Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls. Cancer. 2016;122(2):258–68.

    Article  PubMed  Google Scholar 

  86. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33(12):2971–83.

    Article  PubMed  Google Scholar 

  87. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146–56.

    Article  PubMed  Google Scholar 

  88. Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB. Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2015;9(2):275–84.

    Article  Google Scholar 

  89. Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132(3):1099–106.

    Article  CAS  PubMed  Google Scholar 

  90. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8(1):88–91.

    Article  PubMed  Google Scholar 

  91. Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32(3):480–93.

    Article  PubMed  Google Scholar 

  92. Koppelmans V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp. 2014;35(3):889–99.

    Article  PubMed  Google Scholar 

  93. Jenkins V, Thwaites R, Cercignani M, Sacre S, Harrison N, Whiteley-Jones H, et al. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients. Springerplus. 2016;5:390.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3:444.

    Article  PubMed  PubMed Central  Google Scholar 

  95. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.

    Article  PubMed  Google Scholar 

  97. Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.

    Article  PubMed  Google Scholar 

  98. Scherling C, Collins B, MacKenzie J, Lepage C, Bielajew C, Smith A. Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy. Int J Biol. 2012;4(2):3–25.

    Article  Google Scholar 

  99. Askren MK, Jung M, Berman MG, Zhang M, Therrien B, Peltier S, et al. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat. 2014;147(2):445–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Berman MG, Askren MK, Jung M, Therrien B, Peltier S, Noll DC, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014;33(3):222–31.

    Article  PubMed  Google Scholar 

  101. Churchill NW, Cimprich B, Askren MK, Reuter-Lorenz PA, Jung MS, Peltier S, et al. Scale-free brain dynamics under physical and psychological distress: pre-treatment effects in women diagnosed with breast cancer. Hum Brain Mapp. 2015;36(3):1077–92.

    Article  PubMed  Google Scholar 

  102. Lopez Zunini RA, Scherling C, Wallis N, Collins B, MacKenzie J, Bielajew C, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav. 2013;7(4):460–77.

    Article  PubMed  Google Scholar 

  103. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32(3):324–31.

    Article  PubMed  Google Scholar 

  104. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30(20):2500–8.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci. 2011;5:122.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34(5):543–60.

    Article  PubMed  Google Scholar 

  107. Deprez S, Vandenbulcke M, Peeters R, Emsell L, Smeets A, Christiaens MR, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32(19):2031–8.

    Article  PubMed  Google Scholar 

  108. Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–92.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L, et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One. 2017;12(3):e0171724.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Van Dyk K, Petersen L, Ganz PA. Comparison of neurocognitive function after anthracycline-based chemotherapy vs nonanthracycline-based chemotherapy. JAMA Oncol. 2016;2(7):964–5.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, Hayes DF, et al. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav. 2017;11(1):86–97.

    Article  PubMed  Google Scholar 

  112. Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34(7):677–83.

    Article  CAS  PubMed  Google Scholar 

  113. Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S, et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 2013;7(4):511–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Nudelman KN, Wang Y, McDonald BC, Conroy SK, Smith DJ, West JD, et al. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One. 2014;9(5):e96713.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48(3):329–38.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Cheng H, Li W, Gong L, Xuan H, Huang Z, Zhao H, et al. Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors. Sci Rep. 2017;7:45135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7(4):524–32.

    Article  PubMed  Google Scholar 

  118. Hosseini SM, Kesler SR. Multivariate pattern analysis of FMRI in breast cancer survivors and healthy women. J Int Neuropsychol Soc. 2014;20(4):391–401.

    Article  PubMed  Google Scholar 

  119. Hosseini SM, Koovakkattu D, Kesler SR. Altered small-world properties of gray matter networks in breast cancer. BMC Neurol. 2012;12:28.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A. 2013;110(28):11600–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Miao H, Chen X, Yan Y, He X, Hu S, Kong J, et al. Functional connectivity change of brain default mode network in breast cancer patients after chemotherapy. Neuroradiology. 2016;58(9):921–8.

    Article  PubMed  Google Scholar 

  123. Miao H, Li J, Hu S, He X, Partridge SC, Ren J, et al. Long-term cognitive impairment of breast cancer patients after chemotherapy: a functional MRI study. Eur J Radiol. 2016;85(6):1053–7.

    Article  PubMed  Google Scholar 

  124. Wang L, Yan Y, Wang X, Tao L, Chen Q, Bian Y, et al. Executive function alternations of breast cancer patients after chemotherapy: evidence from resting-state functional MRI. Acad Radiol. 2016;23(10):1264–70.

    Article  PubMed  Google Scholar 

  125. Kesler SR, Adams M, Packer M, Rao V, Henneghan AM, Blayney DW, et al. Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment. Brain Behav. 2017;7(3):e00643.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Amidi A, Hosseini SMH, Leemans A, Kesler SR, Agerbaek M, Wu LM, et al. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. J Natl Cancer Inst. 2017;109(12):9041–4.

    Article  Google Scholar 

  127. Correa DD, Root JC, Baser R, Moore D, Peck KK, Lis E, et al. A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients. Brain Imaging Behav. 2013;7(4):478–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Correa DD, Root JC, Kryza-Lacombe M, Mehta M, Karimi S, Hensley ML, et al. Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav. 2017;11(6):1652–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Correa DD, Wang Y, West JD, Peck KK, Root JC, Baser RE, et al. Prospective assessment of white matter integrity in adult stem cell transplant recipients. Brain Imaging Behav. 2016;10(2):486–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Simó M, Root JC, Vaquero L, Ripolles P, Jove J, Ahles T, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol. 2015;10(1):38–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Stouten-Kemperman MM, de Ruiter MB, Caan MW, Boogerd W, Kerst MJ, Reneman L, et al. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp. 2015;36(11):4638–47.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Chao HH, Hu S, Ide JS, Uchio E, Zhang S, Rose M, et al. Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study. PLoS One. 2013;8(8):e72032.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Chao HH, Uchio E, Zhang S, Hu S, Bednarski SR, Luo X, et al. Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis. BMC Cancer. 2012;12:371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Cherrier MM, Borghesani PR, Shelton AL, Higano CS. Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer. 2010;10(1)

    Google Scholar 

  135. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv: research and practice. 2009;3(4):223–32.

    Article  Google Scholar 

  136. Mak AK, Chaidaroon S, Fan G, Thalib F. Unintended consequences: the social context of cancer survivors and work. J Cancer Surviv: research and practice. 2014;8(2):269–81.

    Article  Google Scholar 

  137. Wagner L, Cella D, Sweet J, Doninger N. Chemotherapy-related cognitive deficits: a qualitative examination of patients and providers. Ann Behav Med. 2003;25:S56.

    Google Scholar 

  138. Myers JS. Cancer- and chemotherapy-related cognitive changes: the patient experience. Semin Oncol Nurs. 2013;29(4):300–7.

    Article  PubMed  Google Scholar 

  139. Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer. 2015;51(4):437–50.

    Article  CAS  PubMed  Google Scholar 

  140. Hines S, Ramis MA, Pike S, Chang AM. The effectiveness of psychosocial interventions for cognitive dysfunction in cancer patients who have received chemotherapy: a systematic review. Worldviews Evid Based Nurs. 2014;11(3):187–93.

    Article  PubMed  Google Scholar 

  141. Morean DF, O'Dwyer L, Cherney LR. Therapies for cognitive deficits associated with chemotherapy for breast cancer: a systematic review of objective outcomes. Arch Phys Med Rehabil. 2015;96(10):1880–97.

    Article  PubMed  Google Scholar 

  142. Sleight A. Coping with cancer-related cognitive dysfunction: a scoping review of the literature. Disabil Rehabil. 2016;38(4):400–8.

    Article  PubMed  Google Scholar 

  143. Treanor CJ, McMenamin UC, O'Neill RF, Cardwell CR, Clarke MJ, Cantwell M, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database Syst Rev. 2016;(8):Cd011325.

    Google Scholar 

  144. Von Ah D, Jansen CE, Allen DH. Evidence-based interventions for cancer- and treatment-related cognitive impairment. Clin J Oncol Nurs. 2014;18(Suppl):17–25.

    Google Scholar 

  145. Zeng Y, Cheng AS, Chan CC. Meta-analysis of the effects of neuropsychological interventions on cognitive function in non-central nervous system cancer survivors. Integr Cancer Ther. 2016;15(4):424–34.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Kesler S, Hadi Hosseini SM, Heckler C, Janelsins M, Palesh O, Mustian K, et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13(4):299–306.

    Article  PubMed  PubMed Central  Google Scholar 

  147. van Heugten CM, Ponds RW, Kessels RP. Brain training: hype or hope? Neuropsychol Rehabil. 2016;26(5-6):639–44.

    Article  PubMed  Google Scholar 

  148. Knowles SE, Lovell K, Bower P, Gilbody S, Littlewood E, Lester H. Patient experience of computerised therapy for depression in primary care. BMJ Open. 2015;5(11):e008581.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007;16(8):772–7.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Ferguson RJ, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology. 2012;21(2):176–86.

    Article  PubMed  Google Scholar 

  151. Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer. 2016;122(11):1782–91.

    Article  PubMed  Google Scholar 

  152. McDonald BC, Flashman LA, Arciniegas DB, Ferguson RJ, Xing L, Harezlak J, et al. Methylphenidate and Memory and Attention Adaptation Training for persistent cognitive symptoms after traumatic brain injury: a randomized, placebo-controlled trial. Neuropsychopharmacology. 2017;42(9):1766–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Caller TA, Ferguson RJ, Roth RM, Secore KL, Alexandre FP, Zhao W, et al. A cognitive behavioral intervention (HOBSCOTCH) improves quality of life and attention in epilepsy. Epilepsy Behav: E&B. 2016;57(Pt A):111–7.

    Article  Google Scholar 

  154. Ferguson RJ, Mittenberg W, Barone DF, Schneider B. Postconcussion syndrome following sports-related head injury: expectation as etiology. Neuropsychology. 1999;13(4):582–9.

    Article  CAS  PubMed  Google Scholar 

  155. Iverson G, Lange R. Examination of “postconcussion-like” symptoms in a healthy sample. Appl Neuropsychol. 2003;10(3):137–44.

    Article  PubMed  Google Scholar 

  156. Wang Y, Chan RC, Deng Y. Examination of postconcussion-like symptoms in healthy university students: relationships to subjective and objective neuropsychological function performance. Arch Clin Neuropsychol: the official journal of the National Academy of Neuropsychologists. 2006;21(4):339–47.

    Article  CAS  Google Scholar 

  157. Ferguson R, Mittenberg W. Cognitive-behavioral treatment of postconcussion syndrome. In: Van Hasselt V, Hersen M, editors. Sourcebook of psychological treatment manuals for adult disorders. Boston, MA: Springer; 1996. p. 615–55.

    Chapter  Google Scholar 

  158. Meichenbaum D. Self-instructional strategy training: a cognitive prothesis for the aged. Hum Dev. 1974;17(4):273–80.

    Article  CAS  PubMed  Google Scholar 

  159. Maguire EA, Valentine ER, Wilding JM, Kapur N. Routes to remembering: the brains behind superior memory. Nat Neurosci. 2003;6(1):90–5.

    Article  CAS  PubMed  Google Scholar 

  160. Ferguson RJ, Cassel AG, Dawson RF. Cognitive effects of cancer chemotherapy in adult cancer survivors: cognitive-behavioral management. J Ration Emot Cogn Behav Ther. 2010;28(1):25–41.

    Article  Google Scholar 

  161. Thayer JF, Hansen AL, Saus-Rose E, Johnsen BH. Heart rate variability, prefrontal neural function, and cognitive performance: the neurovisceral integration perspective on self-regulation, adaptation, and health. Ann Behav Med: a publication of the Society of Behavioral Medicine. 2009;37(2):141–53.

    Article  Google Scholar 

  162. Cicerone KD, Dahlberg C, Kalmar K, Langenbahn DM, Malec JF, Bergquist TF, et al. Evidence-based cognitive rehabilitation: recommendations for clinical practice. Arch Phys Med Rehabil. 2000;81(12):1596–615.

    Article  CAS  PubMed  Google Scholar 

  163. Cicerone KD, Dahlberg C, Malec JF, Langenbahn DM, Felicetti T, Kneipp S, et al. Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil. 2005;86(8):1681–92.

    Article  PubMed  Google Scholar 

  164. Prigatano GP. Principles of neuropsychological Rehabilitation. New York: Oxford University Press; 1999.

    Google Scholar 

  165. Rohling ML, Faust ME, Beverly B, Demakis G. Effectiveness of cognitive rehabilitation following acquired brain injury: a meta-analytic re-examination of Cicerone et al.'s (2000, 2005) systematic reviews. Neuropsychology. 2009;23(1):20–39.

    Article  PubMed  Google Scholar 

  166. Wilson BA. Compensating for cognitive deficits following brain injury. Neuropsychol Rev. 2000;10(4):233–43.

    Article  CAS  PubMed  Google Scholar 

  167. Wilson BA. The clinical neuropsychologist's dilemma. J Int Neuropsychol Soc. 2005;11(4):488–93.

    Article  PubMed  Google Scholar 

  168. Wilson BA. Neuropsychological rehabilitation. Annu Rev Clin Psychol. 2008;4:141–62.

    Article  PubMed  Google Scholar 

  169. Ferguson RJ, Martinson AA. An overview of cognitive-behavioral management of memory dysfunction associated with chemotherapy. Psicooncologia. 2011;8(2-3):385–404.

    Google Scholar 

  170. Kucherer S, Ferguson RJ. Cognitive behavioral therapy for cancer-related cognitive dysfunction. Curr Opin Support Palliat Care. 2017;11(1):46–51.

    PubMed  PubMed Central  Google Scholar 

  171. Lustig C, Shah P, Seidler R, Reuter-Lorenz PA. Aging, training, and the brain: a review and future directions. Neuropsychol Rev. 2009;19(4):504–22.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Sohlberg M, Mateer C. Cognitive rehabilitation: an integrative neuropsychological approach. 2nd ed. New York: The Guilford Press; 2001.

    Google Scholar 

  173. Wagner L, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function Instrument. J Support Oncol. 2009;7(6):W32–W9.

    Google Scholar 

  174. Padgett L, McSpadden K. Barriers and facilitators to implementation of survivorship care: lessons learned from the National Cancer Institute Community Cancer Centers Program. Psychooncology. 2013;22(Suppl 2):1.

    Google Scholar 

  175. Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;(8):Cd007566.

    Google Scholar 

  176. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;(8):Cd008465.

    Google Scholar 

  177. Chang YK, Labban JD, Gapin JI, Etnier JL. The effects of acute exercise on cognitive performance: a meta-analysis. Brain Res. 2012;1453:87–101.

    Article  CAS  PubMed  Google Scholar 

  178. Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2015;(4):Cd005381.

    Google Scholar 

  179. Erickson KI. Therapeutic effects of exercise on cognitive function. J Am Geriatr Soc. 2013;61(11):2038–9.

    Article  PubMed  Google Scholar 

  180. Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(1):3–19.

    Article  Google Scholar 

  181. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ : Can Med Assoc J. 2006;175(1):34–41.

    Google Scholar 

  182. Zimmer P, Baumann F, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int. 2016;2016:1820954.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  183. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133(5):1189–95.

    Article  CAS  PubMed  Google Scholar 

  184. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007;12(Suppl 1):43–51.

    Article  CAS  PubMed  Google Scholar 

  185. Demark-Wahnefried W, Jones LW. Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am. 2008;22(2):319–42. viii

    Article  PubMed  PubMed Central  Google Scholar 

  186. Cappiello M, Cunningham RS, Knobf MT, Erdos D. Breast cancer survivors: information and support after treatment. Clin Nurs Res. 2007;16(4):278–93. discussion 94-301

    Article  PubMed  Google Scholar 

  187. Fitch MI, Gray RE, Godel R, Labrecque M. Young women's experiences with breast cancer: an imperative for tailored information and support. Can Oncol Nurs J = Revue canadienne de nursing oncologique. 2008;18(2):74–86.

    Article  PubMed  Google Scholar 

  188. Jensen RE, Moinpour CM, Potosky AL, Lobo T, Hahn EA, Hays RD, et al. Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort. Cancer. 2017;123(2):327–35.

    Article  PubMed  Google Scholar 

  189. Barlow DH, Bullis JR, Comer JS, Ametaj AA. Evidence-based psychological treatments: an update and a way forward. Annu Rev Clin Psychol. 2013;9:1–27.

    Article  PubMed  Google Scholar 

  190. Barlow DH, Hersen M. Single case experimental designs: strategies for studying behavior change. 2nd ed. New York: Pergamon Press; 1984.

    Google Scholar 

  191. Tate RL, Perdices M, Rosenkoetter U, Shadish W, Vohra S, Barlow DH, et al. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement. Aphasiology. 2016;30(7):862–76.

    Article  PubMed  PubMed Central  Google Scholar 

  192. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl_5):v1–v75.

    Article  PubMed  PubMed Central  Google Scholar 

  193. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14(9):1171–7.

    Article  PubMed  PubMed Central  Google Scholar 

  194. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):1–6.

    Article  PubMed  Google Scholar 

  195. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  196. Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19(20):4037–47.

    Article  CAS  PubMed  Google Scholar 

  197. Hendrix P, Hans E, Griessenauer CJ, Simgen A, Oertel J, Karbach J. Neurocognitive status in patients with newly-diagnosed brain tumors in good neurological condition: the impact of tumor type, volume, and location. Clin Neurol Neurosurg. 2017;156:55–62.

    Article  PubMed  Google Scholar 

  198. van Kessel E, Baumfalk AE, van Zandvoort MJE, Robe PA, Snijders TJ. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment. J Neurooncol. 2017;134(1):9–18.

    Article  PubMed  PubMed Central  Google Scholar 

  199. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47(2):324–33. discussion 33-4

    Article  CAS  PubMed  Google Scholar 

  200. Klein M, Duffau H, De Witt Hamer PC. Cognition and resective surgery for diffuse infiltrative glioma: an overview. J Neurooncol. 2012;108(2):309–18.

    Article  PubMed  PubMed Central  Google Scholar 

  201. Satoer D, Visch-Brink E, Dirven C, Vincent A. Glioma surgery in eloquent areas: can we preserve cognition? Acta Neurochir. 2016;158(1):35–50.

    Article  PubMed  Google Scholar 

  202. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: a review. Front Oncol. 2012;2:73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a dynamic process. Radiat Res. 2000;153(4):357–70.

    Article  CAS  PubMed  Google Scholar 

  204. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HW, et al. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg. 1994;80(2):247–53.

    Article  CAS  PubMed  Google Scholar 

  205. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12(3):627–42.

    Article  CAS  PubMed  Google Scholar 

  206. Salander P, Karlsson T, Bergenheim T, Henriksson R. Long-term memory deficits in patients with malignant gliomas. J Neurooncol. 1995;25(3):227–38.

    Article  CAS  PubMed  Google Scholar 

  207. Scheibel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol. 1996;30(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  208. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159–68.

    Article  PubMed  Google Scholar 

  209. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer. 2004;90(9):1691–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology. 1997;6(3):169–77.

    Article  CAS  PubMed  Google Scholar 

  211. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29(3):272–8.

    Article  PubMed  Google Scholar 

  212. Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–86.

    Article  PubMed  Google Scholar 

  213. Gondi V, Paulus R, Bruner DW, Meyers CA, Gore EM, Wolfson A, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656–64.

    Article  PubMed  PubMed Central  Google Scholar 

  214. Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27(1):78–84.

    Article  PubMed  Google Scholar 

  215. Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res. 2004;162(1):39–47.

    Article  CAS  PubMed  Google Scholar 

  216. Rola R, Raber J, Rizk A, Otsuka S, VandenBerg SR, Morhardt DR, et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol. 2004;188(2):316–30.

    Article  CAS  PubMed  Google Scholar 

  217. Redmond KJ, Mahone EM, Horska A. Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study. Neuro Oncol. 2013;15(11):1455.

    Article  PubMed  PubMed Central  Google Scholar 

  218. Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348–54.

    Article  PubMed  Google Scholar 

  219. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6.

    Article  PubMed  PubMed Central  Google Scholar 

  220. Lin SY, Yang CC, Wu YM, Tseng CK, Wei KC, Chu YC, et al. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: a preliminary report of a prospective phase II study. Biom J. 2015;38(5):439–49.

    Google Scholar 

  221. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.

    Article  PubMed  Google Scholar 

  223. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.

    Article  CAS  PubMed  Google Scholar 

  224. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–95.

    Article  PubMed  Google Scholar 

  225. Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol. 2012;105:903–16.

    Article  PubMed  Google Scholar 

  226. Dietrich J. Chemotherapy associated central nervous system damage. In: Raffa RB, Tallarida RJ, editors. Chemo fog: cancer chemotherapy-related cognitive impairment. New York: Springer; 2010. p. 77–85.

    Chapter  Google Scholar 

  227. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble MCNS. progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22.

    Article  PubMed  PubMed Central  Google Scholar 

  228. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008;13(12):1285–95.

    Article  PubMed  Google Scholar 

  229. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695–708.

    Article  CAS  PubMed  Google Scholar 

  230. Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17(11):e510–e4.

    Article  PubMed  Google Scholar 

  231. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29(33):4430–5.

    Article  PubMed  Google Scholar 

  232. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361–8.

    Article  CAS  PubMed  Google Scholar 

  233. Gehring K, Taphoorn MJ, Sitskoorn MM, Aaronson NK. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. Neurooncol Pract. 2015;2(1):20–31.

    PubMed  PubMed Central  Google Scholar 

  234. Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013;15(10):1420–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  235. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  236. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  237. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–501.

    Article  CAS  PubMed  Google Scholar 

  238. Gehring K, Sitskoorn MM, Gundy CM, Sikkes SA, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27(22):3712–22.

    Article  PubMed  Google Scholar 

  239. Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther. 2012;12(2):255–69.

    Article  CAS  PubMed  Google Scholar 

  240. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol. 2008;7(6):548–60.

    Article  PubMed  Google Scholar 

  241. Bergo E, Lombardi G, Pambuku A, Della Puppa A, Bellu L, D'Avella D, et al. Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art. Biomed Res Int. 2016;2016:3041824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  242. Day J, Gillespie DC, Rooney AG, Bulbeck HJ, Zienius K, Boele F, et al. Neurocognitive deficits and neurocognitive rehabilitation in adult brain tumors. Curr Treat Options Neurol. 2016;18(5):22.

    Article  PubMed  Google Scholar 

  243. Gehring K, Aaronson NK, Taphoorn MJ, Sitskoorn MM. Interventions for cognitive deficits in patients with a brain tumor: an update. Expert Rev Anticancer Ther. 2010;10(11):1779–95.

    Article  PubMed  Google Scholar 

  244. Sherer M, Meyers CA, Bergloff P. Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer. 1997;80(2):250–7.

    Article  CAS  PubMed  Google Scholar 

  245. Locke DE, Cerhan JH, Wu W, Malec JF, Clark MM, Rummans TA, et al. Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study. J Support Oncol. 2008;6(8):383–91.

    PubMed  Google Scholar 

  246. Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.

    Article  CAS  PubMed  Google Scholar 

  247. Correa DD, Kryza-Lacombe M, Baser RE, Beal K, DeAngelis LM. Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol. 2016;127(2):313–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  248. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522–7.

    Article  CAS  PubMed  Google Scholar 

  249. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci. 1995;7(3):347–50.

    Article  CAS  PubMed  Google Scholar 

  250. Wong P, Leppert IR, Roberge D, Boudam K, Brown PD, Muanza T, et al. A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget. 2016;7(32):50986–96.

    Article  PubMed  PubMed Central  Google Scholar 

  251. Kaleita T, Wellisch D, Graham C, Steh B, Nghiemphu P, Ford J, et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol. 2006;24(18_suppl):1503.

    Google Scholar 

  252. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012;107(1):165–74.

    Article  CAS  PubMed  Google Scholar 

  253. Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, et al. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol. 2015;17(10):1393–401.

    Article  PubMed  PubMed Central  Google Scholar 

  254. Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh, Department of Medicine, Division of Hematology/Oncology, Pittsburgh, PA, USA

    Robert J. Ferguson

  2. University of Pittsburgh, School of Nursing, Pittsburgh, PA, USA

    Catherine M. Bender

  3. Indiana University Center for Neuroimaging, Indianapolis, IN, USA

    Brenna C. McDonald

  4. Indiana University Stark Neurosciences Research Institute, Indianapolis, IN, USA

    Brenna C. McDonald

  5. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York City, NY, USA

    James C. Root

  6. University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA, USA

    Shelly Kucherer

Authors
  1. Robert J. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine M. Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenna C. McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James C. Root
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shelly Kucherer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Ferguson .

Editor information

Editors and Affiliations

  1. Professor (ret), Uniformed Services University Founder, Editor in Chief, Journal of Cancer Survivorship: Research and Practice, Bethesda, MD, USA

    Michael Feuerstein

  2. Department of Medicine, Brigham & Women’s Hospital, Perini Family Survivors’ Center, Dana-Farber Cancer Institute, Boston, MA, USA

    Larissa Nekhlyudov

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ferguson, R.J., Bender, C.M., McDonald, B.C., Root, J.C., Kucherer, S. (2018). Cognitive Dysfunction. In: Feuerstein, M., Nekhlyudov, L. (eds) Handbook of Cancer Survivorship. Springer, Cham. https://doi.org/10.1007/978-3-319-77432-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-77432-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-77430-5

  • Online ISBN: 978-3-319-77432-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation